Multi-part substitution infusion fluids and matching anticoagulants
View Patent ↗A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.
1. A two part aqueous substitution infusion fluid for an extracorporeal blood treatment comprising:
a first substitution infusion fluid comprising from about 70 mmol/L to about 130 mmol/L of sodium ion, from about 0.01 mmol/L of potassium ion, from about 100 mmol/L to about 150 mmol/L of chloride ion and from about 0.01 mmol/L to about 1.5 mmol/L of phosphate ion; and
a second aqueous infusion fluid comprising from about 10 mmol/L to about 35 mmol/L of calcium ion, and from about 2.5 mmol/L, to about 20 mmol/L of magnesium ion.
2. The two part aqueous substitution infusion fluid for an extracorporeal blood treatment according to claim 1 wherein said first substitution infusion fluid further comprises from proximately 2 mmol/L to approximately 11.5 mmol/L of glucose.
3. The two part aqueous substitution infusion fluid for an extracorporeal blood treatment according to claim 1 wherein said first substitution infusion fluid further comprises from approximately 5.5 mmol/L to approximately 7.5 mmol/L glucose and wherein said second infusion fluid further comprises calcium ion provided in the form of calcium chloride and magnesium ion provided in the form of magnesium chloride.
4. The two part aqueous substitution infusion fluid for an extracorporeal blood treatment according to claim 2 wherein said second infusion fluid further comprises calcium ion provided in the form of calcium chloride and magnesium ion provided in the form of magnesium sulfate.
5. The two part aqueous substitution infusion fluid for an extracorporeal blood treatment according to claim 2 wherein said second infusion fluid further comprises from about 30 mmol/L to about 100 mmol/L selected from the group consisting of sulphate, gluconate, glubionate and chloride ion.
6. The two part aqueous substitution infusion fluid for an extracorporeal blood treatment according to claim 1 , wherein one of said first substitution infusion fluid and said second infusion fluid comprises from about 0.4 to about 0.8 mmol/L of phosphate ions.
7. The two part aqueous substitution infusion fluid for an extracorporeal blood treatment according to claim 1 , wherein said first substitution infusion fluid comprises about 90 to about 120 mmol/L of sodium ions.
8. The two part aqueous substitution infusion fluid for an extracorporeal blood treatment according to claim 1 , wherein said first substitution infusion fluid comprises between approximately 1.8 and 3.5 mmol/L of potassium ions.
9. The two part aqueous substitution infusion fluid for an extracorporeal blood treatment according to claim 1 , wherein said first substitution infusion fluid comprises between approximately 5.5 and 7.5 mmol/L of glucose.
10. The two part aqueous substitution infusion fluid for an extracorporeal blood treatment according to claim 1 , wherein said first substitution infusion fluid comprises amino acids and/or trace elements.
11. The two part aqueous substitution infusion fluid for an extracorporeal blood treatment according to claim 1 wherein said extracorporeal blood treatment is selected from the group consisting of pure hemofiltration, hemodialysis, hemodiafiltration and continuous plasma filtration absorption.
12. The two part aqueous substitution infusion fluid for an extracorporeal blood treatment according to claim 1 further comprising a matching citrate anticoagulant solution.
13. The two part aqueous substitution infusion fluid for an extracorporeal blood treatment according to claim 12 wherein said matching citrate anticoagulant solution comprises between 19 and 135 mmol/L of citric acid; and between 80 and 550 mmol/L of trisodium citrate.
14. The two part aqueous substitution infusion fluid for an extracorporeal blood treatment according to claim 13 wherein said trisodium citrate comprises between 106 and 300 mmol/L of trisodium citrate.
15. The two part aqueous substitution infusion fluid for an extracorporeal blood treatment according to claim 12 wherein said matching citrate anticoagulant solution comprises about 38–39 mmol/L of citric acid end about 211–212 mmol/L of trisodium citrate.
16. The two part aqueous substitution infusion fluid for en extracorporeal blood treatment according to claim 1 further comprising iron ions, ad/or zinc ions, and/or copper ions, and/or manganese ions, and/or water-soluble vitamins.